181 related articles for article (PubMed ID: 23453541)
1. Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models.
Stegeman H; Kaanders JH; van der Kogel AJ; Iida M; Wheeler DL; Span PN; Bussink J
Radiother Oncol; 2013 Mar; 106(3):383-9. PubMed ID: 23453541
[TBL] [Abstract][Full Text] [Related]
2. EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair.
Stegeman H; Span PN; Cockx SC; Peters JP; Rijken PF; van der Kogel AJ; Kaanders JH; Bussink J
Radiat Res; 2013 Oct; 180(4):414-21. PubMed ID: 24059677
[TBL] [Abstract][Full Text] [Related]
3. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
4. EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
Koi L; Löck S; Linge A; Thurow C; Hering S; Baumann M; Krause M; Gurtner K
Radiother Oncol; 2017 Sep; 124(3):496-503. PubMed ID: 28807520
[TBL] [Abstract][Full Text] [Related]
5. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.
Stegeman H; Kaanders JH; Wheeler DL; van der Kogel AJ; Verheijen MM; Waaijer SJ; Iida M; Grénman R; Span PN; Bussink J
BMC Cancer; 2012 Oct; 12():463. PubMed ID: 23046567
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
[TBL] [Abstract][Full Text] [Related]
9. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
11. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
12. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
[TBL] [Abstract][Full Text] [Related]
13. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
15. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
16. Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.
Guy JB; Méry B; Ollier E; Espenel S; Vallard A; Wozny AS; Simonet S; Lauret A; Battiston-Montagne P; Ardail D; Alphonse G; Rancoule C; Rodriguez-Lafrasse C; Magné N
Sci Rep; 2017 Sep; 7(1):12207. PubMed ID: 28939847
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
18. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
19. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
20. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]